Rahul Kakkar

Rahul joined Polaris Partners in 2021 and serves as an entrepreneur partner. He is a biotech executive and physician-scientist, founding and building biotechnology companies as well as working as a practicing physician.

Most recently, Rahul was Chief Executive Officer at Pandion Therapeutics, a company focused on therapeutics for autoimmune and inflammatory diseases, which he led from Series A through its clinical transition, initial public offering and its ultimate acquisition by Merck for $1.85B. Prior to joining Pandion, Rahul founded Corvidia Therapeutics, a precision cardiovascular company, where he served as Chief Medical Officer and Chief Strategy Officer. Corvidia Therapeutics was acquired by Novo Nordisk for $2.1B. Across his companies, Rahul has led fundraising totaling over $300M to date. Prior to Corvidia, Rahul served as a director in the Emerging Innovations Unit at AstraZeneca, where he was recognized with the AstraZeneca Leadership Recognition Award.

Rahul continues to practice cardiovascular medicine at the Brigham and Women’s Hospital in Boston, and is a lecturer in medicine at Harvard Medical School.

Rahul received his B.A. Cum Laude from Tufts University where he was a member of the Golden Key National Honor Society, and M.D. from the Tufts University School of Medicine, where he was the recipient of the Louis Weinstein Prize in Clinical Medicine and was inducted into the Alpha Omega Alpha Honor Society as a junior. He also served as an Albert Schweitzer Fellow.